FINWIRES · TerminalLIVE
FINWIRES

$CRL

16 stories mentioning CRLUpdated 4d ago

Every FINWIRES story that references CRL, newest first.

What are analysts saying about CRL?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on CRL?

Wire

Charles River Laboratories to Provide Update on New Approach Methodologies Strategy on Investor Day, RBC Says

Charles River Laboratories (CRL) is expected to provide an update on its New Approach Methodologies strategy at its investor day next week, RBC Capital Markets analysts said in a Wednesday note.The European Medicines Agency's pilot program to validate and accept New Approach Methodologies is a "meaningful structural positive," analysts said.RBC expects the company to also provide details on its long-range plan, with detailed growth and margin targets. It expects mid-to-high single-digit growth and margin expansion through 2029.Analysts said they are on the lookout for details on the company's capital allocation, including commentary on accretive growth-oriented mergers and acquisitions in the near term, Discovery and Safety Assessment capacity in China, and the pace of further buybacks.RBC retained an outperform rating and a $282 price target on the stock.Price: $273.08, Change: $+0.20, Percent Change: +0.07%

$CRL
Insider Trading

Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing

Shannon M Parisotto, Corporate Executive Vice President, Discovery & Safety Assessment, on August 19, 2026, sold 2,039 shares in Charles River Laboratories International (CRL) for $599,711. Following the Form 4 filing with the SEC, Parisotto has control over a total of 42,997 common shares of the company, with 4,807 shares held directly and 38,190 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1100682/000110068226000136/xslF345X05/form4.xml

$CRL
Insider Trading

Charles River Laboratories International Insider Sold Shares Worth $1,038,657, According to a Recent SEC Filing

Shannon M Parisotto, Corporate Executive Vice President, Discovery & Safety Assessment, on August 11, 2026, sold 3,714 shares in Charles River Laboratories International (CRL) for $1,038,657. Following the Form 4 filing with the SEC, Parisotto has control over a total of 42,997 shares of the company, with 4,807 shares held directly and 38,190 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1100682/000110068226000130/xslF345X05/form4.xml

$CRL
Insider Trading

Charles River Laboratories International Insider Sold Shares Worth $1,327,098, According to a Recent SEC Filing

Shannon M Parisotto, CEVP, Disc & Safety Assessment, on August 05, 2026, sold 5,046 shares in Charles River Laboratories International (CRL) for $1,327,098. Following the Form 4 filing with the SEC, Parisotto has control over a total of 42,997 common shares of the company, with 4,807 shares held directly and 38,190 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1100682/000110068226000120/xslF345X05/form4.xml

$CRL
Research

JPMorgan Upgrades Charles River Laboratories International to Overweight From Neutral, Adjusts PT to $310 From $180

Charles River Laboratories International (CRL) has an average rating of overweight and mean price target of $268.69, according to analysts polled by FactSet.

$CRL
Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.2%.The iShares Biotechnology ETF (IBB) increased 0.5%.In corporate news, Eli Lilly (LLY) shares rose 4.7% after it posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance. Separately, CVS Health (CVS) said Wednesday it revamped its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. CVS shares were down 3.8%.Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie in a patent-infringement case involving its compounded semaglutide nasal spray. Novo shares added 0.6%.AstraZeneca (AZN) and Bristol Myers Squibb (BMY) are not engaged in discussions over a potential merger, Reuters reported Wednesday, citing a senior source close to the matter. AstraZeneca shares rose 3.5%, and Bristol Myers Squibb fell 3.2%.Charles River Laboratories (CRL) on Wednesday reported fiscal Q2 non-GAAP earnings and sales above market expectations and raised its 2026 non-GAAP EPS guidance. Its shares jumped 11%.

$AZN$BMY$CRL$CVS$LLY$NVO
Sectors

Sector Update: Healthcare

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index rising 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.9%.The iShares Biotechnology ETF (IBB) increased 0.5%.In corporate news, Charles River Laboratories (CRL) on Wednesday reported fiscal Q2 non-GAAP earnings and sales above market expectations and raised its 2026 non-GAAP EPS guidance. Its shares jumped nearly 11%.

$CRL
Wire

Top Midday Gainers

Gran Tierra Energy (GTE) shares soared 37% after the company said Wednesday it agreed to sell its oil business in Colombia and Ecuador to Paris-listed Etablissements Maurel & Prom for an enterprise value of $1.33 billion.More than 18.7 million shares traded intraday, compared with a daily average of about 325,000.Flotek Industries (FTK) raised its 2026 guidance following its Q2 results late Tuesday.Shares jumped 25%, with intraday trading volume rising to more than 1.1 million from a daily average of about 335,000.Charles River Laboratories International (CRL) on Wednesday reported fiscal Q2 non-GAAP earnings and sales above market expectations and raised its 2026 non-GAAP EPS guidance.Shares climbed up 10%, with intraday trading volume rising to over 1.1 million from a daily average of roughly 893,000.Price: $9.37, Change: $+2.54, Percent Change: +37.19%

$CRL$FTK$GTE
Wire

Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating

Charles River Laboratories International (CRL) has an average rating of overweight and mean price target of $237.79, according to analysts polled by FactSet.Price: $231.37, Change: $-2.04, Percent Change: -0.88%

$CRL
Insider Trading

Charles River Laboratories International Insider Sold Shares Worth $16,875,000, According to a Recent SEC Filing

James C Foster, Director, on June 29, 2026, sold 75,000 shares in Charles River Laboratories International (CRL) for $16,875,000. Following the Form 4 filing with the SEC, Foster has control over a total of 233,410 common shares of the company, with 31,596 shares held directly and 201,814 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1100682/000110068226000111/xslF345X05/form4.xml

$CRL
Wire

Charles River Laboratories Shares Rise After Morgan Stanley Upgrade

Charles River Laboratories (CRL) shares rose over 1% on Wednesday after Morgan Stanley upgraded the stock to overweight from equal weight, and adjusted the price target to $220 from $185Trading volume stood at over 464,600 shares compared with a daily average of about 855,500.Price: $186.68, Change: $+1.89, Percent Change: +1.02%

$CRL
Research

Morgan Stanley Upgrades Charles River Laboratories International to Overweight From Equal Weight, Adjusts PT to $220 From $185

Charles River Laboratories International (CRL) has an average rating of overweight and mean price target of $220.29, according to analysts polled by FactSet.

$CRL
Wire

Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says

Charles River Laboratories (CRL) has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.Analysts said that the company's "Pathways to Purpose" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy."We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&D spending growth in 2026 and into 2027," analysts said.RBC has an outperform rating and a $215 price target on the stock.Price: $184.94, Change: $-0.85, Percent Change: -0.46%

$CRL
Research

Research Alert: Charles River Laboratories: Q1 Results Beat, Eps Guidance Unchanged

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Charles River (CRL) delivered Q1 2026 revenue of $995.8M (+1.2% Y/Y, -1.5% organic), beating the $994M consensus, while adjusted EPS of $2.06 (-12.0% Y/Y) exceeded the $1.94 consensus view. Research Models and Services faced headwinds with organic revenue declining 5.5% to $208.4M and operating margin compressing 240 bps to 24.7%, while Discovery and Safety Assessment revenue was flat at $596.9M with margin pressure of 290 bps to 21.0%. CRL successfully completed strategic divestitures of its CDMO and Cell Solutions businesses on May 6, with additional European Discovery Services site sales expected this month. Management maintained yearly guidance for organic sales growth and adjusted EPS despite less favorable FX expectations. Manufacturing Solutions showed resilience with revenue of $190.5M (+2.9% organic) and operating margin improving 280 bps to 25.9% from restructuring cost savings. The company returned $200M to shareholders through repurchases, leaving $800M remaining in authorization.

$CRL
Wire

Charles River Laboratories Positioned as 'Leading' CRO as Preclinical R&D Inflection Nears, RBC Says

Charles River Laboratories International's (CRL) is positioned as the "leading" contract research organization, or CRO, for the acceleration of preclinical research and development into 2027, RBC Capital Markets said in a Monday note.RBC said improving macro conditions appear to be setting up an inflection in research and development spending, potentially starting in H2 and then accelerating through 2027. This expected increase in spending should benefit drive outsourcing to CROs and benefit Charles River Laboratories, the brokerage noted.Charles River Laboratories could also see an opportunity in the ongoing evolution of new alternative methods or NAMs, depending on the company's adoption of NAMS, RBC said.RBC initiated coverage on Charles River Laboratories International with an outperform rating and $215 price target.Price: $181.87, Change: $+3.53, Percent Change: +1.98%

$CRL
Research

RBC Initiates Charles River Laboratories International at Outperform With $215 Price Target

Charles River Laboratories International (CRL) has an average rating of overweight and mean price target of $203.93, according to analysts polled by FactSet.

$CRL

Track with the FINWIRES app suite

FolioX
FolioX
Track CRL in your portfolio
WheelAI
WheelAI
Analyze CRL options with the wheel strategy
StockInsider
StockInsider
See market sentiment on CRL